- Home
- ACIU vs NETD Comparison
ACIU vs NETD Comparison
Compare ACIU & NETD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NETD
- Stock Information
- Founded
- ACIU 2003
- NETD 2023
- Country
- ACIU Switzerland
- NETD United States
- Employees
- ACIU N/A
- NETD N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NETD
- Sector
- ACIU Health Care
- NETD
- Exchange
- ACIU Nasdaq
- NETD Nasdaq
- Market Cap
- ACIU 213.3M
- NETD 241.5M
- IPO Year
- ACIU 2016
- NETD 2023
- Fundamental
- Price
- ACIU $2.04
- NETD $11.30
- Analyst Decision
- ACIU Strong Buy
- NETD
- Analyst Count
- ACIU 1
- NETD 0
- Target Price
- ACIU $12.00
- NETD N/A
- AVG Volume (30 Days)
- ACIU 109.7K
- NETD 4.4K
- Earning Date
- ACIU 08-05-2025
- NETD 01-01-0001
- Dividend Yield
- ACIU N/A
- NETD N/A
- EPS Growth
- ACIU N/A
- NETD N/A
- EPS
- ACIU N/A
- NETD 0.20
- Revenue
- ACIU $36,362,036.00
- NETD N/A
- Revenue This Year
- ACIU N/A
- NETD N/A
- Revenue Next Year
- ACIU $1,022.98
- NETD N/A
- P/E Ratio
- ACIU N/A
- NETD $55.15
- Revenue Growth
- ACIU 86.71
- NETD N/A
- 52 Week Low
- ACIU $1.43
- NETD $10.58
- 52 Week High
- ACIU $3.98
- NETD $11.47
- Technical
- Relative Strength Index (RSI)
- ACIU 44.83
- NETD 63.47
- Support Level
- ACIU $2.05
- NETD $11.21
- Resistance Level
- ACIU $2.19
- NETD $11.24
- Average True Range (ATR)
- ACIU 0.11
- NETD 0.02
- MACD
- ACIU -0.01
- NETD 0.00
- Stochastic Oscillator
- ACIU 4.55
- NETD 90.91
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NETD Nabors Energy Transition Corp. II
Nabors Energy Transition Corp II is a blank check company.